To help you get started, we've assembled links to various sections of the site (in the right-hand column), and we encourage you to check out the press releases and the glossary (where you can satisfy your curiosity about idiopathic thrombocytopenic purpura and the difference between IGIV and IVIG).

If you still don't see what you need, please call our media line at (+1) 919 316 6316. Inquiries from journalists only please.

Quick Facts:

	Talecris is headquartered in the biotech hub of Research Triangle Park, NC, USA. Additional regional headquarters are located in Toronto, Canada, and Frankfurt, Germany.
	Talecris employees, more than 4,000 worldwide, include outstanding scientists and business professionals recognized by peers, partners, patients, and professionals as passionate and committed to their work.
	Our primary manufacturing facility is in Clayton, NC, USA; additional fractionation capacity and contract manufacturing is provided by our facility in Melville, NY.
	Our Clayton, NC, facility was recently honored as an Industry Week 2007 Best Plants Finalist in recognition of its excellent performance metrics.
	Talecris discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis.
	Talecris Plasma Resources, Inc. (TPR), a wholly owned subsidiary of Talecris Biotherapeutics, is a network of plasma collection centers that provides the source material for the production of Talecris’ critical care protein therapies.
	Talecris' revenues exceeded approximately $1.2 billion in 2007.
	Between its launch in 2005 through the end of 2007, Talecris invested in excess of $550 million to support the growth of the business.
	Talecris was named a "Fast 50" award winner, recognizing it as one of Research Triangle Park's fastest-growing privately held companies. The award honors privately owned businesses and their contribution to the growth and success of the entire community.